Femistra 1mg Tablet

Most side effects of Femistra 1mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine.

In case these side effects become worse, consult your doctor immediately.

• Constipation
  
• Diarrhea
  
• Weight gain, Heartburn Loss of appetite
  
• Hair thinning
  
• Tingling of hands and feet
  
• Trouble sleeping
  
• Dizziness
  
• Chest pain
  
• Swelling of hands
  
• Yellowing of skin and eyes
  
• Vision complications
  
• Vaginal bleeding

The doctor prescribes this medicine; hence, it is advisable to follow the prescription. Femistra tablets are taken orally once a day, and they can be taken with or without food as advised by the doctor. Femistra tablet should be taken at the same time every day for maximum benefits. Contact your doctor or any healthcare provider in case of an overdose and seek medical attention immediately.

In many breast cancers, estrogen stimulates the uncontrollable growth of cancerous cells. Aromatase enzyme, present mainly in the adrenal glands can convert the androgens to estrogen, and this estrogen furthermore influences the cancerous cells. Thus, Femistra is a non-steroidal inhibitor that competitively binds to the aromatase enzyme and stops the production of estrogen. As a result, it inhibits the growth and spreading of the tumor cells.

If you forget to take a dose of Femistra 1mg tablet consult your doctor. Don’t double up the next dose to cope with the missed one unless your doctor recommends it.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. Miller, W. R., Bartlett, J., Brodie, A. M., et al. (2020). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors, and do they matter? The Oncologist, 13(8), 829–837 - https://silice.csic.es/publication/2f55f7a9-252c-4d4b-bf88-950931448c35
2. Anderson, W. F., Chatterjee, N., Ershler, W. B., et al. (2022). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Research and Treatment, 76(1), 27–36 - https://pubmed.ncbi.nlm.nih.gov/12408373/
3. Miller, W., Stuart, M., Sahmoud, T., et al. (2023). Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. British Journal of Cancer, 87(9), 950–955 - https://pubmed.ncbi.nlm.nih.gov/12434282/
4. Yang, Y., Pan, W., Tang, X., Wu, S., & Sun, X. (2025). A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget, 8(29), 48362–48374 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5564654/
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies, C., Godwin, J., et al. (2021). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet, 378(9793), 771–784 - https://pubmed.ncbi.nlm.nih.gov/21802721/
6. Ingle, J. N., Suman, V. J., Ma, C. X., et al. (2025). Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids, 99(Pt A), 32–38 - https://pmc.ncbi.nlm.nih.gov/articles/PMC4339673/
7. Cairns, J., Ingle, J. N., Liu, M. C., et al. (2023). The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Research, 21(1), 47 - https://pmc.ncbi.nlm.nih.gov/articles/PMC6448248/
8. Tang, M. R., Wang, Y. X., Guo, S., Han, S. Y., & Wang, D. (2022). CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis, 17(9), 927 - https://pubmed.ncbi.nlm.nih.gov/22538441/